Search Results
Your search for ,ARE matches 21430 pages
Showing 6251 - 6300Expert Point of View: James Essell, MD
James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other CAR T-cell products being evaluated for indolent...
ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
Expert Point of View: John C. Krauss, MD
The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...
Expert Point of View: Michael J. Overman, MD
The study’s invited discussant, Michael J. Overman, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, said the findings of the study presented by Henriksen et al1 add to a convincing body of data showing that “the use of circulating...
Predicting Postoperative Recurrence in Stage I to III Colorectal Cancer With Circulating Tumor DNA
Patients with stage I to III colorectal cancer who have a high risk for recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA proved more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Expert Point of View: Rachna T. Shroff, MD
Invited discussant of the ClarIDHy trial, Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said positive findings for ivosidenib support the notion that “biliary cancer is a perfect example of...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Benefits Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Tuya Pal, MD, Named to Cancer Research National Leadership Posts
Tuya Pal, MD, Ingram Professor of Cancer Research and Associate Director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts. She is the incoming Editor-in-Chief of the National Cancer Institute’s Physician Daily Query (PDQ)...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
The Lustgarten Foundation and AACR Honor Two American Icons by Establishing New Career Development Awards
The Lustgarten Foundation and the American Association for Cancer Research (AACR) have announced two new career development awards for early-career female and underrepresented pancreatic cancer researchers, representing a commitment of the Lustgarten Foundation of up to $1.8 million. The awards...
Understanding Patients’ Needs and Preferences: Cancer Care Stakeholders Explore Barriers and Best Practices
The keynote speaker did not mince words. “I tell everyone, do not use the term age-appropriate therapy,” said Jan White, a cancer survivor and patient advocate who described her own experience with stage IV non-Hodgkin lymphoma. “Patients with cancer,” she said, “are more than their age, gender,...
NCCN Shares New Recommendations for Vaccinating Patients With Cancer Against COVID-19
The National ComprehensiveCancer Network® (NCCN) has released new guidance1 on vaccinating people with cancer against COVID-19. The nonprofit alliance of leading cancer centers created an NCCN COVID-19 Vaccine Committee, which includes hematology and oncology experts with particular expertise in...
Expert Point of View: Jacob Soumerai, MD
Jacob Soumerai, MD, Assistant Professor at Harvard Medical School and Massachusetts General Hospital Cancer Center, who was not involved in this study, commented on the MURANO study findings. “MURANO is the definitive phase III trial that established venetoclax/rituximab as a standard of care for...
Janet Woodcock, MD, Named Acting FDA Commissioner
Janet Woodcock, MD, current Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA), has been named acting FDA Commissioner, according to a report published in The New York Times.1Stephen M. Hahn, MD, who had been FDA Commissioner since December 17,...
Gene Therapy Pioneer Arthur W. Nienhuis, MD, Dies at 79
Gene therapy pioneer Arthur W. Nienhuis, MD, the fourth Director of St. Jude Children’s Research Hospital, died on February 3 at age 79. Under his leadership, the hospital grew exponentially in both size and scientific stature. “At St. Jude, the nature of our work requires a bold, ambitious...
HERO-TOGETHER: Opportunity for Health-Care Workers to Share Their Experience With COVID-19 Vaccination
HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people fare after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health-care providers everywhere have worked together to face. On the...
Role of Twitter in Identifying Barriers to Care Among Patients With Metastatic Breast Cancer
Information shared by women with metastatic breast cancer on social media platforms like Twitter may be a timely source of data for policymakers hoping to improve care and outcomes for these patients, according to a study published by Shimkhada et al in JMIR Public Health and Surveillance. Role of...
Mental Health–Related Symptoms Among Cancer Survivors During the First Wave of the COVID-19 Pandemic in the United States
In an analysis from the COVID-19 Impact Survey reported in JCO Oncology Practice, Islam et al found that U.S. adult cancer survivors were more likely to report mental health–related symptoms vs adults without cancer during the first wave of the COVID-19 pandemic. Study Details Data for the analysis ...
Delay in Time Between Abnormal At-Home Screening and Colonoscopy May Increase Colorectal Cancer Risk
At-home tests, which measure blood in stool as a potential marker for colon cancer, are often used for colorectal cancer screening. Usage of these tests has increased during the COVID-19 pandemic as patients try to avoid clinical visits. However, effectiveness of these screening tools, along with...
Lisocabtagene Maraleucel Approved by FDA for Patients With Relapsed or Refractory Large B-Cell Lymphoma
On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not...
FDA Update: Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate, Statement on Product Development to Address Virus Variants
On February 4, the U.S. Food and Drug Administration (FDA) announced the scheduling of a meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the request for emergency use authorization for a COVID-19 vaccine from Janssen Biotech Inc. Additionally, Acting...
Study Shows Aspirin Use Before Diagnosis May Lower Colorectal Cancer Mortality
A recent study found that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower colorectal cancer–specific mortality. The report, published by Figueiredo et al in JNCI: The Journal of the National Cancer Institute, suggests that the findings for prediagnosis...
HIC Assays May Aid in Predicting Response to Immunotherapy Among Patients With NSCLC
Using a host immune classifier (HIC) test for patients with non–small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented by Akerley et al at the International Association for the Study of Lung Cancer (IASLC) 2020 World...
Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection
B-cell–depleting immunotherapy may cause B-cell aplasia and impair the body’s immune response. A retrospective, multicentric French study of patients with lymphoma and persistent COVID-19 infection has found that those treated with B-cell–depleting therapies within the previous 12 months had nearly ...
Socially Distant Drive-by FluFIT Clinics May Increase Colorectal Cancer Screening Rates Among Black Patients During the COVID-19 Pandemic
Administering colorectal cancer screening kits through a socially distant drive-by flu vaccination clinic increased access to colorectal cancer screening among Black Americans, according to results presented by Washington et al at the AACR Virtual Meeting: COVID-19 and Cancer (Abstract S02-04)....
Study Finds More Than Half of U.S. Cancer Survivors Have Underlying Medical Conditions Associated With Severe COVID-19 Illness
A recent study has found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness. The report, published by Jiang et al in JNCI: The Journal of the National Cancer Institute, suggested that...
Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO
More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...
Germline Whole-Exome Sequencing Reveals the Potential Role of Hereditary Predisposition and Therapeutic Implications in SCLC
A study presented by Nobuyuki Takahashi, MD, of the Center for Cancer Research at the National Cancer Institute, at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore (Abstract OA11.05) demonstrated that there may be an inherited ...
Patient-Reported Outcomes From the CROWN Trial: First-Line Lorlatinib vs Crizotinib for ALK-Positive NSCLC
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration in chest pain, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented at the International Association for the Study of...
Development and Performance of a Population-Based Benchmark Model for Use of Cancer Surgery in High-Income Countries
In a study reported in The Lancet Oncology, Perera et al developed a population-based benchmark model for guideline-recommended use of surgery for primary cancers in high-income countries. Actual use of surgery was often consistent with model predictions but sometimes varied markedly. Study ...
Taiwanese TALENT Study Supports Effectiveness of Low-Dose CT for Lung Cancer in Certain Populations
A study presented by researchers with the Ministry of Health and Welfare in Taiwan confirmed low-dose computed tomography (CT) screening may be feasible in a predefined, never-smoking, high-risk population. The research was presented at the International Association for the Study of Lung Cancer...
Two ADAURA Analyses Support the Use of Osimertinib in Patients With Surgically Resected NSCLC
Two presentations based on data from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival outcomes for patients with surgically resected non–small cell lung cancer (NSCLC) receiving osimertinib, while also maintaining quality of life. The data were...
Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk
In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
WCLC Press Briefing Focuses on the Connection Between Lung Cancer and COVID-19
On February 27, 2020, the Journal of Thoracic Oncology published a case study that described two patients from Wuhan, China, who had recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. Eleven months later, the lung...
Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma
In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...
LCMC3 Trial: Neoadjuvant Atezolizumab for Patients With Stage IB to IIIB Resectable Lung Cancer
Neoadjuvant treatment with single-agent atezolizumab for patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and pathologic complete response rate of 7% in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study. The findings were...
Adolescent and Young Adult Cancer Survivors Are at Increased Risk for Adverse Mental Health Outcomes
According to the National Cancer Institute, in 2020, 89,500 adolescents and young adults (AYAs) aged 15 to 39 were diagnosed with cancer, and of these, 84.6% are expected to survive their cancer for 5 years after diagnosis. However, the results from a study by De et al published in the Journal of...
Emil J Freireich, MD, Dies at 93
Emil J Freireich, MD, an oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized as a founding father of modern clinical cancer research, passed away on February 1. He was 93. Dr. Freireich was a faculty member at The University of Texas MD Anderson Cancer ...
Addition of Wee1 Inhibitor Adavosertib to Gemcitabine in Platinum-Resistant/Refractory Recurrent Ovarian Cancer
In a phase II trial reported in The Lancet, Lheureux et al found that the addition of the oral Wee1 inhibitor adavosertib to gemcitabine significantly improved progression-free survival in patients with platinum-resistant/refractory recurrent ovarian cancer. As related by the investigators, the...
Featured Presentations at WCLC Focus on Disparities in Patients With Lung Cancer
At a press briefing held by the International Association for the Study of Lung Cancer (IASLC), researchers presented new data that revealed factors relating to race, gender, sexual orientation, and income continue to be significant barriers to those living with lung cancer. The press briefing is...
Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC
The phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in patients with advanced non–small cell lung cancer (NSCLC). In a follow-up to phase I data, the phase II cohort of the study has now shown a durable response rate of 37.1%, a disease control rate...
‘State of Tobacco Control’ 2021 Report Says Ending Tobacco Use Is Critical, Especially During the COVID-19 Pandemic
Even amid the COVID-19 pandemic, tobacco use remains a serious public health threat. In addition to tobacco-related death and disease, smoking also increases the risk of the most severe impacts of COVID-19. The American Lung Association has released its 19th annual “State of Tobacco Control”...
Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy
Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-reported outcomes with physician assessments of four common radiation-associated symptoms: pain, pruritus, ...
Shorter Radiation Course for Men With Advanced Prostate Cancer: Safety and Efficacy
A study led by researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center found that shortening a traditional 45-day course of radiation to a 5-day course delivered in larger doses was safe and as effective as conventional radiation for men with high-risk...
New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on screening in survivors’ later years. The guidelines, published today by Rachel A. Freedman, MD, MPH, and ...
World Cancer Day 2021 to Focus on Adaptations and Innovations in Cancer Care Through COVID-19 and Beyond
To mark World Cancer Day on February 4, the Union for International Cancer Control (UICC) will give voice to and say thank you to the nurses, doctors, researchers, volunteers, advocates, and other caregivers in oncology from around the world, as well as government agencies, who have worked through...
FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer
The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Early Research Explores Relationship Between CD58 Loss and Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to an experimental study presented...
